Alphamab Oncology
康宁杰瑞
Executive Summary
Alphamab Oncology is a Suzhou-based biotech focused on oncology therapeutics, trading on Hong Kong Stock Exchange. The company appears to have clear BIOSECURE status, making it potentially attractive for US partnerships without regulatory complications. Limited public information on recent corporate activities and leadership suggests either a low-profile operational phase or potential data gaps requiring deeper due diligence.
Structure: As a Hong Kong-listed Chinese biotech, Alphamab likely operates through a traditional holding company structure rather than a VIE arrangement, given its clear BIOSECURE status. The company's Suzhou headquarters places it in a major biotech hub, suggesting access to talent and infrastructure, though specific subsidiary relationships require investigation.
Ownership & Shareholder Structure
Alphamab Oncology → AstraZeneca
Alphamab envafolimab (PD-L1 single-domain antibody) partnership with AZ for subcutaneous oncology.
Clinical Trials(50 total)
4
Phase 3
4
Phase 2
7
Phase 1
5
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07391644 | JSKN027 | Ph.1 | NOT YET RECRUITING | 250 |
| NCT07475559 | JSKN016HC | Ph.1 | NOT YET RECRUITING | 42 |
| NCT07336771 | JSKN016 Q2W, JSKN016 Q3W, D-0502 | Ph.1, Ph.2 | NOT YET RECRUITING | 60 |
| NCT07283198 | JSKN033 Injection | Ph.2 | NOT YET RECRUITING | 160 |
| NCT07292402 | JSKN022 | Ph.1 | RECRUITING | 225 |
| NCT06747416 | KN057 | Ph.2 | NOT YET RECRUITING | 24 |
| NCT07201467 | KN060 | Ph.1, Ph.2 | RECRUITING | 12 |
| NCT07191899 | KN060, 0.9% Sodium Chloride Injection | Ph.1 | RECRUITING | 60 |
| NCT06942234 | JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin, Pembrolizumab | Ph.1, Ph.2 | RECRUITING | 180 |
| NCT06868732 | JSKN016, Carboplatin, Furmonertinib Mesylate, Ivonescimab, Docetaxel, Tislelizumab, Pembrolizumab | Ph.1 | NOT YET RECRUITING | 288 |
| NCT06775483 | JSKN016, Docetaxel | Ph.2 | NOT YET RECRUITING | 220 |
| NCT06770881 | JSKN033 | Ph.1, Ph.2 | NOT YET RECRUITING | 430 |
| NCT06751485 | JSKN003, Doxorubicin, Paclitaxel, Topotecan | Ph.3 | NOT YET RECRUITING | 430 |
| NCT06547775 | KN069 | Ph.1 | RECRUITING | 36 |
| NCT06592417 | JSKN016 injection | Ph.1 | RECRUITING | 140 |
| NCT06569108 | KN057 | Ph.3 | ACTIVE NOT RECRUITING | 125 |
| NCT06226766 | JSKN033 Injection | Ph.1, Ph.2 | TERMINATED | 11 |
| NCT06312475 | KN057 | Ph.3 | ACTIVE NOT RECRUITING | 53 |
| NCT06180889 | Enoxaparin, KN060 Low, KN060 Middle, KN060 Hight | Ph.2 | ACTIVE NOT RECRUITING | 241 |
| NCT06079983 | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Ph.3 | RECRUITING | 400 |
Showing 20 of 50 trials
BIOSECURE Risk
Company has clear BIOSECURE status and is not designated under BCC categories, indicating minimal regulatory risk for US partnerships
Key Exposures:
- •Potential indirect relationships with designated entities
- •Supply chain dependencies on restricted vendors
Mitigation: Clear status suggests existing compliance measures, but specific mitigation strategies unknown
BD Intelligence
Therapeutic Areas:
Recent Deals: No recent deal activity recorded, suggesting either stealth mode operations or limited partnership focus
Approach: Approach with preliminary pipeline assessment and management identification; low BIOSECURE risk makes this a potentially clean partner for US deals
Red Flags
- ⚠Limited public disclosure on management team
- ⚠No recorded recent corporate events or deal activity
- ⚠Sparse pipeline information available
Quick Facts
- Key People
- 0
- Subsidiaries
- 0
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 0
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 0
- Drug Molecules
- 0
- Relationships
- 1
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (0 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.